Inhibrx Biosciences Inc (INBX)

$69.26 +0.52 (0.76%)
Market Cap 999.75M
Revenue (ttm) 200,000.00
Net Income (ttm) 1.69B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 843,784.96%
Debt to Equity Ratio 1.45
Volume 146,900
Avg Vol 186,264
Day's Range N/A - N/A
Shares Out 14.54M
Stochastic %K 23%
Beta 1.50
Analysts Hold
Price Target $12.00

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 795 4220
Website: inhibrx.com
Address:
11025 North Torrey Pines Road, Suite 140, La Jolla, United States
Doorkey
Doorkey Mar. 14 at 6:41 PM
$INBX "Why haven't you posted lately?" Because I made a shit ton of money...
0 · Reply
justiceforb_85
justiceforb_85 Mar. 12 at 10:41 PM
$INBX decent data for ozekibart in relapsed Ewing sarcoma. Impressive ORR compared with IRI/TMZ and no significant hepatotoxicity noted. Hopefully FDA will allow for AA.
0 · Reply
justiceforb_85
justiceforb_85 Mar. 10 at 6:57 PM
$INBX added. Look forward to Ewing sarcoma data to be presented on 3/12.
0 · Reply
TrendTrade8696
TrendTrade8696 Feb. 23 at 2:42 PM
$INBX New DECK filed: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000002/inhibrxpresentation_febr.htm
2 · Reply
MyrtleLockwood880
MyrtleLockwood880 Feb. 21 at 8:42 AM
$INBX Inhibrx develops biologic therapies. Pipeline progress drives valuation. Early-stage biotech risk remains.
0 · Reply
LiquidityWanderer
LiquidityWanderer Feb. 18 at 9:29 AM
$INBX CNS-focused biotech with binary events; volatility is expected, not anomalous.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 4:43 PM
$INBX Current Stock Price: $77.61 Contracts to trade: $80.0 INBX Feb 20 2026 Call Entry: $0.25 Exit: $0.44 ROI: 76% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Gtrading1234
Gtrading1234 Feb. 15 at 5:52 AM
$INBX
0 · Reply
GrowthGrabber
GrowthGrabber Feb. 4 at 2:18 PM
$INBX is a clinical-stage biotech developing antibody therapies for inflammatory and fibrotic diseases; its pipeline is promising but remains in early-stage development.
0 · Reply
TrendTrade8696
TrendTrade8696 Feb. 2 at 3:18 PM
$INBX 1,650,847 shares short... How long can these guy's hold their nose?
0 · Reply
Latest News on INBX
Inhibrx Announces Participation in Upcoming Scientific Conference

Mar 2, 2026, 4:00 PM EST - 14 days ago

Inhibrx Announces Participation in Upcoming Scientific Conference

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too

Jan 13, 2026, 3:09 PM EST - 2 months ago

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too

Why Inhibrx's Recent Strength May Not Be Built to Last

Dec 24, 2025, 7:33 AM EST - 2 months ago

Why Inhibrx's Recent Strength May Not Be Built to Last

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Dec 16, 2025, 5:00 PM EST - 3 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 6:00 AM EST - 4 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Inhibrx Announces Participation in Upcoming Scientific Conferences

Nov 4, 2025, 4:01 PM EST - 4 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Oct 24, 2025, 3:31 PM EDT - 5 months ago

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 6:39 PM EDT - 5 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 23, 2025, 4:05 PM EDT - 5 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 5 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Reports Second Quarter 2025 Financial Results

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 10 months ago

Inhibrx Reports First Quarter 2025 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 5, 2024, 11:45 AM EST - 1 year ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Aug 27, 2024, 7:10 AM EDT - 1 year ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 7, 2024, 2:42 PM EDT - 1 year ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

Jun 5, 2024, 7:46 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 24, 2024, 4:00 PM EDT - 1 year ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Sanofi to Buy Rare-Disease Assets From Inhibrx

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Andreas Halvorsen's Firm Ups Inhibrx Stake

Sep 1, 2023, 4:26 PM EDT - 2 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Inhibrx Announces $200 Million Private Placement Financing

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Announces $200 Million Private Placement Financing

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 17, 2023, 4:41 PM EDT - 2 years ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 7, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Inhibrx: Undercovered Company With Good Potential

Apr 13, 2023, 11:12 AM EDT - 3 years ago

Inhibrx: Undercovered Company With Good Potential

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Doorkey
Doorkey Mar. 14 at 6:41 PM
$INBX "Why haven't you posted lately?" Because I made a shit ton of money...
0 · Reply
justiceforb_85
justiceforb_85 Mar. 12 at 10:41 PM
$INBX decent data for ozekibart in relapsed Ewing sarcoma. Impressive ORR compared with IRI/TMZ and no significant hepatotoxicity noted. Hopefully FDA will allow for AA.
0 · Reply
justiceforb_85
justiceforb_85 Mar. 10 at 6:57 PM
$INBX added. Look forward to Ewing sarcoma data to be presented on 3/12.
0 · Reply
TrendTrade8696
TrendTrade8696 Feb. 23 at 2:42 PM
$INBX New DECK filed: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000002/inhibrxpresentation_febr.htm
2 · Reply
MyrtleLockwood880
MyrtleLockwood880 Feb. 21 at 8:42 AM
$INBX Inhibrx develops biologic therapies. Pipeline progress drives valuation. Early-stage biotech risk remains.
0 · Reply
LiquidityWanderer
LiquidityWanderer Feb. 18 at 9:29 AM
$INBX CNS-focused biotech with binary events; volatility is expected, not anomalous.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 4:43 PM
$INBX Current Stock Price: $77.61 Contracts to trade: $80.0 INBX Feb 20 2026 Call Entry: $0.25 Exit: $0.44 ROI: 76% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Gtrading1234
Gtrading1234 Feb. 15 at 5:52 AM
$INBX
0 · Reply
GrowthGrabber
GrowthGrabber Feb. 4 at 2:18 PM
$INBX is a clinical-stage biotech developing antibody therapies for inflammatory and fibrotic diseases; its pipeline is promising but remains in early-stage development.
0 · Reply
TrendTrade8696
TrendTrade8696 Feb. 2 at 3:18 PM
$INBX 1,650,847 shares short... How long can these guy's hold their nose?
0 · Reply
TrendTrade8696
TrendTrade8696 Jan. 31 at 1:53 AM
$INBX Great tape today!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 11:00 PM
$INBX RSI: 42.31, MACD: -1.3481 Vol: 2.61, MA20: 75.59, MA50: 79.62 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dr_Stoxx
Dr_Stoxx Jan. 22 at 3:02 PM
$INBX biotech looks good here. Perfect MACD setup. Lng-term cycle is dodgy but intermed. term is perfectly placed. Putting it on the GREENS list.
0 · Reply
cubie
cubie Jan. 13 at 4:39 PM
$CAI $INBX $GPCR $VKTX @judgeyoung2 nailed it, how whales know do deep itm on $GPCR on friday
0 · Reply
cubie
cubie Jan. 9 at 8:52 PM
$CAI $INBX $GPCR $VKTX So only one left that's interesting is gpcr 🤔😁
0 · Reply
TrendTrade8696
TrendTrade8696 Jan. 7 at 3:42 PM
$INBX https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 4:06 PM
$INBX RSI: 32.70, MACD: 1.2650 Vol: 4.35, MA20: 83.46, MA50: 75.75 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RugRestore
RugRestore Dec. 26 at 5:24 PM
$INBX Risk appetite is present but conditioned on validation. Forecast discipline should become more precise and conservative. Confidence weakens if progress becomes episodic rather than consistent. The trajectory strengthens as results compound visibly.
0 · Reply
WheatWhisperer
WheatWhisperer Dec. 24 at 10:49 AM
$INBX Forward visibility remains uneven as management navigates capital constraints while advancing core initiatives. Long-term optimism depends on disciplined follow-through.
0 · Reply
Okadarlan
Okadarlan Dec. 23 at 5:28 PM
$INBX -11 % is just the start @IjustTradeiT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 3:58 PM
$INBX RSI: 48.99, MACD: 2.7277 Vol: 3.87, MA20: 84.20, MA50: 73.18 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CycleTrade
CycleTrade Dec. 23 at 2:37 PM
$INBX is thinking about breaking out
0 · Reply